ACAD
Price
$24.84
Change
+$0.01 (+0.04%)
Updated
Jul 24 closing price
Capitalization
4.25B
17 days until earnings call
Intraday BUY SELL Signals
RIGL
Price
$36.74
Change
-$0.08 (-0.22%)
Updated
Jul 24 closing price
Capitalization
679.03M
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs RIGL

ACAD vs RIGL Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. RIGL commentary
Jul 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2026
Stock price -- (ACAD: $24.84 vs. RIGL: $36.74)
Brand notoriety: ACAD and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 46% vs. RIGL: 72%
Market capitalization -- ACAD: $4.25B vs. RIGL: $679.03M
ACAD [@Biotechnology] is valued at $4.25B. RIGL’s [@Biotechnology] market capitalization is $679.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, RIGL is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 5 bearish.
  • RIGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -2.97% price change this week, while RIGL (@Biotechnology) price change was -9.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.

Reported Earning Dates

ACAD is expected to report earnings on Aug 11, 2026.

RIGL is expected to report earnings on Aug 04, 2026.

Industries' Descriptions

@Biotechnology (-4.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($4.25B) has a higher market cap than RIGL($679M). ACAD has higher P/E ratio than RIGL: ACAD (11.24) vs RIGL (1.90). ACAD YTD gains are higher at: -7.001 vs. RIGL (-14.219). RIGL has higher annual earnings (EBITDA): 131M vs. ACAD (92.7M). ACAD has more cash in the bank: 851M vs. RIGL (147M). RIGL has less debt than ACAD: RIGL (45.7M) vs ACAD (50.8M). ACAD has higher revenues than RIGL: ACAD (1.1B) vs RIGL (300M).
ACADRIGLACAD / RIGL
Capitalization4.25B679M626%
EBITDA92.7M131M71%
Gain YTD-7.001-14.21949%
P/E Ratio11.241.90591%
Revenue1.1B300M365%
Total Cash851M147M579%
Total Debt50.8M45.7M111%
FUNDAMENTALS RATINGS
ACAD vs RIGL: Fundamental Ratings
ACAD
RIGL
OUTLOOK RATING
1..100
8282
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
269
PRICE GROWTH RATING
1..100
4640
P/E GROWTH RATING
1..100
8399
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RIGL's Valuation (34) in the Biotechnology industry is in the same range as ACAD (64). This means that RIGL’s stock grew similarly to ACAD’s over the last 12 months.

RIGL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that RIGL’s stock grew similarly to ACAD’s over the last 12 months.

RIGL's SMR Rating (9) in the Biotechnology industry is in the same range as ACAD (26). This means that RIGL’s stock grew similarly to ACAD’s over the last 12 months.

RIGL's Price Growth Rating (40) in the Biotechnology industry is in the same range as ACAD (46). This means that RIGL’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's P/E Growth Rating (83) in the Biotechnology industry is in the same range as RIGL (99). This means that ACAD’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADRIGL
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
70%
Momentum
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 30 days ago
74%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signal:
Gain/Loss:
RIGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CDDYX41.410.34
+0.83%
Columbia Dividend Income Inst3
ICIEX24.47N/A
N/A
Nomura Core Equity Fund Class I
FMEUX34.64N/A
N/A
Franklin Mutual International Value R6
BAFYX12.38N/A
N/A
Brown Advisory Sustainable Sml-Cp Cr Ins
CNWIX28.54-0.78
-2.66%
Calamos Evolving World Growth I

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with ACAD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then ACAD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
-0.22%
ACAD - RIGL
38%
Loosely correlated
+0.04%
AKBA - RIGL
33%
Loosely correlated
N/A
VCYT - RIGL
32%
Poorly correlated
-2.19%
IOVA - RIGL
32%
Poorly correlated
-2.73%
PROK - RIGL
32%
Poorly correlated
-1.32%
More